With a market cap of $11.3 billion, Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells reagents, instruments, and services for research, diagnostics, and bioprocessing applications. It operates through its Protein Sciences and Diagnostics and Spatial Biology segments, providing innovative solutions for life science research, cell and gene therapy, molecular diagnostics, and spatial biology.
The Minneapolis, Minnesota-based company is slated to announce its fiscal Q4 2026 results soon. Ahead of the event, analysts expect TECH to report an EPS of $0.46, down 9.8% from $0.51 in the year-ago quarter. However, it has surpassed or met Wall Street's bottom-line estimates in each of the past four quarterly reports.